Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures: 2017-2022

  • Arcus Biosciences' Gains from Sales and Divestitures rose 30.83% to $500,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $500,000, marking a year-over-year increase of 30.83%. This contributed to the annual value of $500,000 for FY2022, which is 30.83% up from last year.
  • Arcus Biosciences' Gains from Sales and Divestitures amounted to $500,000 in Q4 2022, which was up 30.83% from $382,183 recorded in Q4 2021.
  • Arcus Biosciences' 5-year Gains from Sales and Divestitures high stood at $500,000 for Q4 2022, and its period low was $6,250 during Q4 2020.
  • Its 3-year average for Gains from Sales and Divestitures is $296,144, with a median of $382,183 in 2021.
  • Per our database at Business Quant, Arcus Biosciences' Gains from Sales and Divestitures tumbled by 98.32% in 2020 and then surged by 6,014.93% in 2021.
  • Over the past 5 years, Arcus Biosciences' Gains from Sales and Divestitures (Quarterly) stood at $14,918 in 2018, then soared by 2,398.82% to $372,774 in 2019, then plummeted by 98.32% to $6,250 in 2020, then spiked by 6,014.93% to $382,183 in 2021, then skyrocketed by 30.83% to $500,000 in 2022.
  • Its Gains from Sales and Divestitures was $500,000 in Q4 2022, compared to $382,183 in Q4 2021 and $6,250 in Q4 2020.